Synergy Vision MD appointed as trustee of the Cystic Fibrosis Trust

pharmafile | June 17, 2016 | News story | Medical Communications Synergy Vision, appointment, cystic fibrosis, cystic fibrosis trust, medical communications, medical communications agency 

Managing director of Synergy Vision Ffyona Dawber has been appointed to the Cystic Fibrosis Trust’s board of trustees.  Her wealth of experience in healthcare stems from running a successful medical communications agency, a decade of working in the pharmaceutical industry, and working with patients directly as a nurse.

Commenting on her appointment, Dawber says:  “I feel strongly that everyone should have access to understandable information about their condition and the medications they are taking. I have both friends and family living with cystic fibrosis, each of whom have inspired me to raise awareness about the real-life impact of the condition.

“I believe it is a very exciting time right now – CF research is a huge focus for both academia and the pharmaceutical industry.  It feels like we are starting to turn a corner in identifying long-awaited treatments.”

Further information contact:

Caroline Brown

Tel: +44(0)20 7625 0050

Email: caroline.brown@synergy-vision.com           

Related Content

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

Arcturus Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan …

vertex-headquarters

Vertex applies to expand indication of cystic fibrosis drug

Vertex has announced that the EMA and MHRA have validated the post marketing applications for …

EC approves Kaftrio as combination treatment for cystic fibrosis

Vertex Pharmaceuticals has been granted European Commission approval for the label extension of Kaftrio (ivacaftor/tezacaftor/elexacaftor) …

Latest content